Notice: This company has been marked as potentially delisted and may not be actively trading. Immuron (IMRN) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsHeadlinesShort InterestTrends IMRN vs. RLYB, UNCY, VTVT, IMNN, XLO, IMMX, VYNE, RVPH, HOOK, and CARMShould you be buying Immuron stock or one of its competitors? The main competitors of Immuron include Rallybio (RLYB), Unicycive Therapeutics (UNCY), vTv Therapeutics (VTVT), Imunon (IMNN), Xilio Therapeutics (XLO), Immix Biopharma (IMMX), VYNE Therapeutics (VYNE), Reviva Pharmaceuticals (RVPH), Hookipa Pharma (HOOK), and Carisma Therapeutics (CARM). These companies are all part of the "pharmaceutical preparations" industry. Immuron vs. Rallybio Unicycive Therapeutics vTv Therapeutics Imunon Xilio Therapeutics Immix Biopharma VYNE Therapeutics Reviva Pharmaceuticals Hookipa Pharma Carisma Therapeutics Immuron (NASDAQ:IMRN) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership, community ranking and media sentiment. Does the MarketBeat Community believe in IMRN or RLYB? Immuron received 149 more outperform votes than Rallybio when rated by MarketBeat users. However, 76.47% of users gave Rallybio an outperform vote while only 67.87% of users gave Immuron an outperform vote. CompanyUnderperformOutperformImmuronOutperform Votes18867.87% Underperform Votes8932.13% RallybioOutperform Votes3976.47% Underperform Votes1223.53% Does the media prefer IMRN or RLYB? In the previous week, Rallybio had 4 more articles in the media than Immuron. MarketBeat recorded 6 mentions for Rallybio and 2 mentions for Immuron. Rallybio's average media sentiment score of 0.65 beat Immuron's score of 0.00 indicating that Rallybio is being referred to more favorably in the news media. Company Overall Sentiment Immuron Neutral Rallybio Positive Do analysts rate IMRN or RLYB? Immuron currently has a consensus price target of $5.00, indicating a potential upside of 159.07%. Rallybio has a consensus price target of $9.75, indicating a potential upside of 865.35%. Given Rallybio's higher probable upside, analysts plainly believe Rallybio is more favorable than Immuron.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuron 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Rallybio 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has more volatility and risk, IMRN or RLYB? Immuron has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, Rallybio has a beta of -1.67, meaning that its share price is 267% less volatile than the S&P 500. Do insiders & institutionals have more ownership in IMRN or RLYB? 0.1% of Immuron shares are held by institutional investors. Comparatively, 90.3% of Rallybio shares are held by institutional investors. 7.0% of Immuron shares are held by company insiders. Comparatively, 7.4% of Rallybio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is IMRN or RLYB more profitable? Immuron's return on equity of 0.00% beat Rallybio's return on equity.Company Net Margins Return on Equity Return on Assets ImmuronN/A N/A N/A Rallybio N/A -77.39%-69.33% Which has stronger valuation & earnings, IMRN or RLYB? Immuron has higher revenue and earnings than Rallybio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmuron$3.21M3.45-$4.55MN/AN/ARallybioN/AN/A-$74.56M-$1.60-0.63 SummaryImmuron and Rallybio tied by winning 7 of the 14 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Immuron News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMRN vs. The Competition Export to ExcelMetricImmuronPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.34M$6.81B$5.23B$8.99BDividend YieldN/A8.04%4.97%4.05%P/E RatioN/A5.0888.9313.36Price / Sales3.45395.001,290.0291.57Price / CashN/A53.5139.6236.46Price / Book1.329.726.516.00Net Income-$4.55M$154.47M$118.67M$225.40M Immuron Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMRNImmuron1.7787 of 5 stars$1.93-2.5%$5.00+159.1%+2.1%$11.34M$3.21M0.00N/AShort Interest ↓Gap DownRLYBRallybio3.3557 of 5 stars$1.01-7.3%$9.75+865.3%-57.7%$45.22MN/A-0.6340UNCYUnicycive Therapeutics3.3049 of 5 stars$0.45-6.3%$5.13+1,044.0%-13.8%$45.11M$680,000.00-0.469Analyst ForecastAnalyst RevisionVTVTvTv Therapeutics0.535 of 5 stars$15.64+5.0%N/A+11.7%$44.85M$2.02M-3.459Gap DownIMNNImunon3.0333 of 5 stars$0.75flat$12.00+1,504.3%-21.3%$44.84M$500,000.00-0.4033Short Interest ↑Analyst RevisionGap UpXLOXilio Therapeutics2.4949 of 5 stars$0.96-4.0%$4.00+317.8%-26.9%$43.85MN/A-0.5673Short Interest ↑IMMXImmix Biopharma3.0981 of 5 stars$1.62+3.2%$7.00+332.1%-63.2%$43.19MN/A-1.919Earnings ReportPositive NewsVYNEVYNE Therapeutics2.5298 of 5 stars$2.84-2.4%$5.75+102.5%-20.4%$41.89M$493,000.00-3.3030Short Interest ↑RVPHReviva Pharmaceuticals3.0171 of 5 stars$1.21-3.2%$15.50+1,181.0%-77.9%$41.80MN/A-0.935News CoveragePositive NewsHOOKHookipa Pharma2.7534 of 5 stars$3.14-8.2%$44.67+1,322.5%-31.9%$41.23M$20.13M-0.7356Short Interest ↑CARMCarisma Therapeutics3.2763 of 5 stars$0.94-3.1%$7.00+645.6%-64.6%$40.63M$14.92M-0.6020Short Interest ↓ Related Companies and Tools Related Companies RLYB Competitors UNCY Competitors VTVT Competitors IMNN Competitors XLO Competitors IMMX Competitors VYNE Competitors RVPH Competitors HOOK Competitors CARM Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMRN) was last updated on 11/15/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTop "Sleeping Giant" Crypto In The Market NowTop "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your fi...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuron Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
